Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody.
Li JX, Tan SY, Li LQ, Zheng YH, Zhao L, Zhu HR, He HL, Zhang YY, Li RZ, Bao TY, Zhang YZ, Yang XM, Zhang H, Chen HH, Wu BW, Lin X, Lin XS, Lin YC, Sui XB, Xie Y, Zhou XM, Yan PY.
Li JX, et al. Among authors: lin x, lin xs.
Front Pharmacol. 2025 Jun 17;16:1594213. doi: 10.3389/fphar.2025.1594213. eCollection 2025.
Front Pharmacol. 2025.
PMID: 40599804
Free PMC article.